Bio Usawa
San Francisco, US · Founded 2023 · Delaware corporation
Bio Usawa is a biotechnology company that develops and manufactures affordable monoclonal antibodies and biologic medicines, with a focus on bringing cancer and other therapies to patients in Africa and globally.
BiotechHealthtechImpact & Social Good
Founders & leadership
MB
Menghis BairuExecutive Officer, Director
JH
John HautmanExecutive Officer
MB
Mengistu BairuCo-founder & CEO
DC
Denise ChinFounder & Board Member
RC
Richard ChinDirector
VA
Vincent AncinettiDirector
Competitors · 4
by search overlapUmoja Biopharma, Inc.4 shared keywordsUmoja Biopharma develops in vivo CAR T cell therapies for cancer treatment using its VivoVec platform, which generates CAR T cells directly in patients' bodies. The company operates its own manufacturing facility to produce these cancer immunotherapies.
Yemaachi Biotechnology3 shared keywordsYemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.
Nanoporetech3 shared keywordsOxford Nanopore develops DNA and RNA sequencing technology, including devices for library preparation, sequencing, and data analysis tools such as EPI2ME. Its products serve researchers studying areas like the human genome, microbiome, and biodiversity, with real-time, scalable workflows.
Thumbnail for Seragon Pharmaceuticals3 shared keywords
Companies competing with Bio Usawa for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$500KraisedJan 2026 · 7 investors · BiotechnologyRule 506(b)
▶$500KraisedJan 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard ChinDirector
- Vincent AncinettiDirector
- John HautmanExecutive Officer
- Menghis BairuExecutive Officer, Director
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$1.7MraisedDec 2025 · 25 investors · BiotechnologyRule 506(b)
▶$1.7MraisedDec 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard ChinDirector
- Menghis BairuExecutive Officer, Director
- John HautmanExecutive Officer
- Vincent AncinettiDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Minimum investment
- $5K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$403.9KraisedDec 2025 · 5 investors · BiotechnologyRule 506(b)
▶$403.9KraisedDec 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vincent AncinettiDirector
- Richard ChinDirector
- John HautmanExecutive Officer
- Menghis BairuExecutive Officer, Director
- Offering amount
- $403.9K
- Amount sold
- $403.9K
- Minimum investment
- $25K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.